Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 22,009 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Blood Glucose, Blood Insulin
Interventions: Beverage 1, Beverage 2, Beverage 3, Beverage 4, Beverage 5, Beverage 6; Dietary Supplement
Lead sponsor: Ocean Spray Cranberries, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Metastatic Melanoma
Interventions: Secukinumab Injection; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia, Chemoradiation
Interventions: Pneumonia vaccine; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement; Procedure · Drug · Dietary Supplement
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Stroke, Rehabilitation, Hand
Interventions: transcranial direct current stimulation and electrical stimulator; Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Interventions: HWK-016, MUCIN-16-targeted ADC, Bevacizumab; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more

Conditions: CMV, Allogeneic Stem Cell Transplantation
Interventions: Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR; Drug · Device · Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Orange, California

Conditions: Biliary Tract Cancers
Interventions: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion; Biological · Drug · Other
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Irvine, California • Los Angeles, California • Orange, California + 4 more

Conditions: Pelvic Metastasis
Interventions: Photodynamic nails; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Intra-Abdominal Hypertension
Interventions: Accuryn Foley catheter device; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Spatial Navigation
Interventions: Active 10-Hz TMS to the parietal cortex, Active single pulse TMS to the parietal cortex, Sham 10-Hz TMS to the right parietal cortex, Sham single-pulse rTMS the rigt parietal cortex; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Oropharyngeal Carcinoma
Interventions: 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires; Diagnostic Test · Combination Product · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Chronic Leukemia Myelogenous
Interventions: Bosulif; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 20 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Marginal Zone Lymphoma
Interventions: Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 4
States / cities: Duarte, California • Miami, Florida • Atlanta, Georgia + 1 more

Conditions: Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder
Interventions: Exposure-Based Therapy; Behavioral
Lead sponsor: Jasper A. Smits; Other
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Austin, Texas

Conditions: Preeclampsia (PE)
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6,550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Glendale, Arizona • Newark, Delaware • Miami, Florida + 15 more

Conditions: Firearm Injury
Interventions: Store Safely; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Negaunee, Michigan

Conditions: Obstructive Sleep Apnea (OSA), OSA, Healthy Volunteers, Electromyography
Interventions: Electromyography (EMG) of the Oropharynx; Diagnostic Test
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypertension, Resistant to Conventional Therapy
Interventions: Minocycline Hydrochloride, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Intubation Complication, Adverse Events
Interventions: tracheal intubation; Other
Lead sponsor: Thomas Riva; Other
Eligibility: Up to 16 Years
Enrollment: 105,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Spinal Cord Injuries, Endothelial Dysfunction
Interventions: Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling; Procedure
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Interventions: Moderate-intensity continuous training (MCT), Resistance training, Weight loss; Behavioral · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: 225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11, 177Lu-PSMA-I&T; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Search by objective public record fields.

Postprandial Response to Fruit Juice

IL-17 Blockade to Decrease irAEs (REPLAY)

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Improving Stroke Motor Control With Non-invasive Brain Stimulation and Functional Electrical Stimulation

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome

Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter

Modulating Goal-directed Navigation Using Noninvasive Brain Stimulation

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

Non-Invasive Preeclampsia Screening and Biobank

Store Safely: Rural Firearm Injury Prevention for Families

Diagnosing Obstructive Sleep Apnea Using Electromyography of the Muscles of the Mouth

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation

Endothelial Dysfunction After SCI

Tailored Exercise Training Study Among Adults With HFpEF

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer